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Abstract: Relatively low levels of antioxidant enzymes and high oxygen metabolism result 
in formation of numerous oxidized DNA lesions in the tissues of the central nervous 
system. Accumulation of damage in the DNA, due to continuous genotoxic stress, has been 
linked to both aging and the development of various neurodegenerative disorders. Different 
DNA repair pathways have evolved to successfully act on damaged DNA and prevent 
genomic instability. The predominant and essential DNA repair pathway for the removal of 
small DNA base lesions is base excision repair (BER). In this review we will discuss the 
current knowledge on the involvement of BER proteins in the maintenance of genetic 
stability in different brain regions and how changes in the levels of these proteins 
contribute to aging and the onset of neurodegenerative disorders. 
Keywords: brain; neurodegeneration; reactive oxygen species; DNA damage;  
base excision repair 
 
1. Introduction 
Our genome is under constant genotoxic stress. Endogenous agents, such as reactive oxygen species 
(ROS) produced during physiological cellular metabolism, have the potential to attack the DNA 
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molecules, thus generating various oxidized lesions (reviewed in [1,2]). Additional sources of DNA 
damage represent exogenous insults, like ionizing radiation and UV-light exposure. As the 
maintenance of genomic integrity is of highest priority, living organisms have evolved multiple 
molecular mechanisms to repair damaged DNA. An inability to remove various types of DNA 
damages results in a broad spectrum of pathologies, such as neuronal deficits, immunodeficiencies, 
premature aging and cancer (reviewed in [3]). 
Post-mitotic cells, like neurons of the central nervous system (CNS) possess a limited selection of 
the canonical DNA repair pathways, which makes them particularly sensitive to further DNA damage 
response (DDR) deficiencies [4]. A functional and efficient DDR is therefore of crucial importance to 
ensure their survival. Since neurons that are lost are generally not replaced, DNA repair is essential to 
sustain brain homeostasis. Given the high oxygen metabolism of the brain and the relatively low levels 
of antioxidant enzymes, ROS-induced oxidized DNA lesions represent a major type of neuronal DNA 
damage (reviewed in [5,6]). 7,8-dihydro-8-oxo-guanine (8-oxo-G) is one of the most frequently 
generated oxidized DNA lesions and thus often used as a marker of oxidative stress and ROS-damage. 
The predominant DNA repair pathway enabling efficient removal of small base damages due to ROS, 
alkylating agents or spontaneous decay, is base excision repair (BER) (Figure 1). This pathway is 
carried out through either short-patch (SP-) or long-patch BER (LP-BER) subpathways. The SP-BER 
(Figure 1A) is initiated by one of the eleven lesion-specific DNA glycosylases, grouped in three 
classes (monofunctional, bifunctional, endonuclease VIII (Nei)-like proteins (NEIL)) [7], which 
recognize and excise the damaged base from the DNA by hydrolyzing the N-glycosidic bond. In the 
case of monofunctional glycosylases (such as uracil N-glycosylase (UNG), single-strand-specific 
monofunctional uracil DNA glycosylase 1 (SMUG1), methyl-CpG binding domain protein (MBD4), 
thymine DNA glycosylase (TDG), MutY glycosylase homologue (MUTYH) and alkyladenine DNA 
glycosylase (AAG)), upon hydrolysis of the N-glycosidic bond an abasic (AP) site is generated and the 
DNA backbone is subsequently cleaved by the apurinic/apyrimidinic endonuclease 1 (APE1), 
producing a single nucleotide (1 nt) gap with 3'-hydroxyl (3'-OH) and a 5'-deoxyribose phosphate  
(5'-dRP) moiety, respectively. In addition to the N-glycosidic hydrolysis, bifunctional glycosylases 
(like 8-oxoguanine DNA glycosylase (OGG1) and Endonuclease III-like 1 (NTHL1)) cleave the 
phosphodiester backbone by β-elimination, through the AP lyase activity, giving rise to a 3' terminal 
sugar phosphate (3'-ddR5P) and a 5'-phosphate residue. The 3'-ddR5P is further processed by APE1, 
resulting in a 1nt gap with 3'-OH terminus. In case the repair is initiated by NEIL1/2/3 glycosylases, 
after N-glycosidic hydrolysis, processing of the termini by β,δ-elimination is catalyzed, resulting in 3'- 
and 5'-phosphate residues, respectively. The 3'-phosphate is thereafter cleaved by polynucleotide 
kinase (PNK), producing a 1nt gap with 3'-OH terminus. In all situations the 1nt gap, created during 
SP-BER, will be filled by DNA polymerase (Pol) β through incorporation of one nucleotide. If the 
repair was initiated by monofunctional glycosylases, a polymerisation step is followed by Pol β 5'-dRP 
lyase activity. A newly synthetized product contains 3'-OH and 5'-phosphate termini that can be ligated 
by the X-ray repair cross complementing 1 protein (XRCC1)/DNA ligase III complex. If Pol β dRP 
lyase activity can not process the 5' terminus created through glycosylase independent APE1 directed 
incision of natural AP sites (AP) or 2'-deoxyribonolactone (2'-dRL) residues, as well as oxidation or 
reduction of 5'-deoxyribose fragment, LP-BER subpathway (Figure 1B) will take place. Removal of 
such a blocking 5' moiety can occur either through: (i) strand-displacement DNA synthesis where a 
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switch to Pols δ or ε takes place after incorporation of first nucleotide by Pol β [8–11], or (ii) the  
Hit-and-Run mechanism by alternating flap endonuclease 1 (FEN1) cleavage and Pols β synthesis 
(reviewed in [2,12]). Extension by Pol δ/ε is mediated through displacement of the downstream strand, 
generating a 5'-flap that can be recognized and cleaved by FEN1. The resulting 3'-OH and  
5'-phosphate termini are finally ligated by DNA ligase I. 
Figure 1. Short-patch (SP-) and long-patch base excision repair (LP-BER) sub-pathways. The 
damaged base is recognized and excised by a DNA glycosylase, resulting often in AP site 
formation, which is further processed by APE1. Subsequent end-processing generates  
3'-OH and 5'-phosphate (5'-P) termini, enabling access of repair Pols. Depending on the 
number of newly incorporated nucleotides, the BER pathway divides into two  
sub-pathways: short-patch BER (SP-BER) and long-patch BER (LP-BER). (A) In SP-BER, 
a Pol β-mediated single nucleotide incorporation is followed by strand ligation, catalyzed 
by the XRCC1/DNA ligase III complex; (B) In contrast, LP-BER synthesizes a repair 
patch consisting of 2–12 nucleotides by: (i) the Hit-and-Run mechanism involving 
alternating FEN1 cleavage and Pols β synthesis; or (ii) the strand-displacement DNA 
synthesis concerted by Pols β and δ/ε. The 5'-flap, created during strand-displacement 
DNA synthesis, is removed by the FEN1 generating a nick. The FEN1 created nick is 
sealed by DNA ligase I. For more details see text. 
 
Numerous studies in the past decades strongly associate the accumulation of DNA lesions, induced 
by DNA repair deficiencies, with a broad spectrum of progressive neurodegenerative disorders. Thus, 
the aim of this review is to summarize the current knowledge of the deficiencies in BER proteins 
associated with neurodegeneration and to illustrate the pivotal role of efficient oxidative DNA damage 
repair needed to protect the neurons of the CNS. We will present the findings gained from the various 
studies by following the proteins in the order they appear in the BER pathway (Table 1). 
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Table 1. Overview of BER proteins and their involvement in physiology and pathology of the 
brain. The information listed is an overview of the data presented in the manuscript text. ↑ 
stands for up-regulation or an increase, while ↓ signifies either down-regulation or decrease.  
Protein Physiological 
expression in brain 
Expression changes  
induced by 
Changes associated with 
neurodgenerative disorders 
Brain specific effect of 
knockout/knockdown  Protein family 
D
N
A
 g
ly
co
sy
la
se
s 
H
el
ix
-h
ai
rp
in
-h
el
ix
 fa
m
ily
 
OGG1 
- ↓ postnatal  
- ↑ from 8 weeks  
- ↓ age-dependently 
↑ 
- cigarette smoke  
- dieldrin-proliferating 
cells  
- SIF in murine brains 
PD - ↑ - differentiation shift-
neural to astrocytic lineage
- mild PD phenotype with 
age  
- ↑ sensitivity to 
dopaminergic substances 
and ischemia-induced 
DNA damage  
- combination with CSB 
kd—no effect on CS 
phenotype 
ALS 
- S326C increased risk  
- ↑ in presymptomatic SOD1 
mice  
↓ 
- dieldrin-differentiated 
cells  
- fenvalerate 
HD 
- OGG1 increases TNR 
instability, especially the 
S326C  
- ↓ in striatum of HD mice  
No 
change 
- lead (Pb)  
Stroke/  
Ischemia 
- various effects depending 
on the model used 
AD - ↑ but also ↓ observed 
MUTYH 
- ↑ in neonate and 
adult brain  
- ↓ with age  
None reported 
PD - ↑  
None reported 
Stroke/  
Ischemia 
- mainly ↑  
Other 
disorders 
- possibly ↓ in equine 
cerebellar abiotrophy 
 MBD4 None reported None reported 
Diverse 
disorders 
- ↑ in schizophrenia and 
bipolar disorder patients  
None reported 
 NTHL1 None reported None reported 
Diverse 
disorders 
- no association with MS risk  None reported 
En
do
nu
cl
ea
se
 V
II
I-
lik
e 
NEIL1 - ↑ mid-age, during 
differentiation  
- ↓ with age  
- minor changes in 
hippocampal 
mitochondria over 
lifespan 
None reported Stroke/  
Ischemia 
- no changes by OGD in 
hippocampal slice cultures, 
↓ by hypothermia 
- impaired memory and 
increased brain damage 
after ischemia/reperfusion 
in ko mice 
NEIL2 - ↑ during 
differentiation 
None reported Stroke/  
Ischemia 
- no changes after OGD None reported 
NEIL3 - stem cell rich 
regions, also in early 
embryos 
- ↓ with age 
None reported Stroke/  
Ischemia 
- ↓ in hypoxia - ko with ↓ neuronal 
progenitors and NSC 
differentiation ability 
 
AAG - highly expressed in 
several brain regions 
None reported  None reported  - ko results in suppression, 
while Tg in increase of 
toxicity induced by 
alkylating agents 
U
D
G
 UNG - varying expression 
depending on brain 
region and age 
None reported AD/TNR 
disorders 
- changed in tauopathies and 
↓ in AD patients  
- ko and Tg with 
neurodegeneration  
- ko ↑ ischemic infarct size 
 TDG None reported None reported None reported - ko embryonic lethal  
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Table 1. Cont. 
Protein Physiological 
expression in brain 
Expression changes induced by
Changes associated with 
neurodgenerative disorders 
Brain specific effect of 
knockout/knockdown   Protein family 
E
nd
on
uc
le
as
es
 
  APE1 - ↓ with age  ↑ 
- 100% O2 in brains 
of young rats, but 
not in old ones 
AD 
- ↑ levels in patients, 
varying expression upon Aβ 
treatment 
- ↑ levels of p-APE1 (less active) 
- no significant correlation 
with D148E 
None reported 
PD 
- ↑ levels of p-APE1  
(less active) 
HD 
- 2-fold increase in 
cerebellum HD mice 
Stroke/  
ischemia 
- ↓ in several models of 
hypoxia, hypothermia, 
stroke and trauma 
Other 
diseases 
 
- ↓ in AOA patients  
- both ↑ and ↓ in ALS 
patients detected  
- association of missense 
mutations, D148E  
- ↑ in epilepsia model 
FEN1 None reported None reported HD - implicated in TNR 
expansion, increased in 
cerebellum of HD mice  
None reported 
 PNK - low expression  None reported MCSZ - multiple mutations 
associated 
None reported 
D
N
A
 p
ol
ym
er
as
es
 Pol β 
- constitutive 
expression  
- ↓ activity with age  
None reported 
AD - Aβ induced Pol β-mediated 
cell cycle reentrance, 
neuronal loss and 
differentiation of neural 
progenitors to neuronal 
lineage  
- MPP + induces Pol  
β-mediated cell cycle 
reentrance and cell death  
- neonatal lethal, altered 
neurogenesis in ko mice, 
which is p53 dependent 
and more pronounced in 
a DNA-PKcs ko 
background  
HD - Pol β accumulation along 
CAG repeats in striatum of 
HD mice 
Stroke/  
ischemia 
- ↑ in several models  
 
Pol δ + 
Pol ε None reported None reported 
HD - Pol δ blocks TNR 
expansion together with 
Srs2 and resolves  
TNR‐based hairpin 
structures together with 
WRN 
None reported 
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Table 1. Cont. 
Protein Physiological 
expression in brain 
Expression changes 
induced by 
Changes associated with 
neurodgenerative disorders 
Brain specific effect of 
knockout/knockdown  Protein family 
Sc
af
fo
ld
in
g 
 XRCC1 None reported None reported 
AD 
- R194W and R399 ↑ risk,  
no effect by R280H/R399Q 
- XRCC1nes−cre ko mice 
age-dependent 
accumulation of DNA 
damage, loss of certain 
neurons in the 
cerebellum and altered 
hippocampal 
homeostasis 
HD 
- 2-fold increase in 
cerebellum HD mice 
Stroke/  
ischemia 
- ↓ in several models of 
ischemia, hypothermia 
Other 
diseases 
- ↑ levels in some parts of the 
brains of Down’s syndrome 
patients, and ↓ in others 
- ↑ levels in a rat epilepsia 
model 
D
N
A
 li
ga
se
s 
 
DNA 
ligase I 
- moderate in 
cerebellum, lateral 
ventricle and cerebral 
cortex  
- ↓ in hippocampus 
and striatum  
 HD 
- 2-fold ↑ in cerebellum HD 
mice 
- essential for 
embryonic development 
 
DNA 
ligase III 
- ↑ in cerebellum and 
cerebral cortex  
- moderate in 
hippocampus and 
lateral ventricle 
 
SCAN 
- association due to 
interaction with TDP1? 
- essential for 
embryonic development 
AOA1 - association? 
2. DNA Glycosylases 
2.1. The Helix-Hairpin-Helix DNA Glycosylases 
2.1.1. OGG1 
8-oxoguanine DNA glycosylase (OGG1) is a bifunctional DNA glycosylase that removes oxidized bases 
such as 8-oxo-G, 2,6-diamino-4-hydroxy-5-formamidopyrimidine (FaPyG) and 7,8-dihydro-8-oxoadenine 
(8-oxo-A) from the DNA ([13–22], and reviewed in [2]). Importantly, while OGG1 removes 8-oxo-G 
and FaPyG when base pared to a natural cytosine (C), 8-oxo-A will not be removed when paired to 
native thymine (T). OGG1 is expressed in at least four different splice forms in mammalian cells, of 
which at least two contribute differentially to BER pathways removing 8-oxo-G from nuclear (nDNA) 
and mitochondrial DNA (mtDNA) [23]. By catalyzing the excision of an oxidatively damaged base, 
OGG1 initiates a canonical SP-BER pathway that involves the action of APE1, Pol β and 
XRCC1/DNA ligase III to reconstitute the original intact base pair.  
It is known that oxidative DNA damage plays a role in the process of ageing. OGG1 as one of the 
main regulators of 8-oxo-G levels in the genome, was shown to be widely expressed and active in 
human as well as rodent brains [24]. Initial transient decrease in OGG1 expression directly upon birth 
of mice, was followed by an increase after 8 weeks of age. Along this line, using a Comet-assay 
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analysis of DNA damage in isolated neurons and astrocytes from the cortex of young (7 days), adult  
(6 months) and old (2 years) rats, Swain et al. revealed an age-dependent increase in the number of 
OGG1-sensitive sites, accompanied by a decrease in the OGG1 activity [25]. Further, by testing the 
activity of neuronal extracts from rat cerebral cortices in an in vitro assay with synthetic 
oligonucleotide duplexes, the authors observe a marked decline of 8-oxo-G repair capacity with age [26]. 
The decline could be attributed to a decrease in the expression levels of OGG1 and other BER 
enzymes including APE1 and Pol β. Supplementation of the neuronal extracts with the reduced 
components individually did not result in rescuing of the BER activity, suggesting that the  
age-dependent decline was not a result of an overall deficiency in the single DNA repair factors. 
However, addition of OGG1 together with Pol β and T4 DNA ligase markedly improved the BER 
activity and thus suggested that several BER proteins are limiting factors in adult and old neurons.  
Acetylation of OGG1 has been shown to promote its enzymatic activity up to 10-fold in vitro [27]. 
Analysis of the OGG1 acetylation status in brain neurons of young rats revealed an increase in the 
acetylated form of OGG1 associated with either exercise or insulin-like growth factor-1 (IGF-1) 
treatment, a factor known to enhance neurogenesis [28]. In contrast, total OGG1 levels, as well as the 
amount of the acetylated OGG1 form, decreased with age in rats and correspondingly 8-oxo-G levels 
increased. The age-associated decrease in neurogenesis was possible to attenuate with exercise and 
IGF-1 treatment; at the same time exercise also improved the spatial memory, while IGF-1 treatment 
inhibited this process. These findings could potentially underline a role of oxidative DNA damage in 
age-related neuropathologies. Ogonovszky et al. further showed that neither were the levels of 8-oxo-G nor 
the OGG1 activity altered by exercise training in rats, suggesting that over-training does not induce 
oxidative stress in the brain and does not cause loss of memory [29]. 
Besides investigating the impact of the age-related decline on cellular level, studies of the mtDNA 
repair in particular revealed an association between DNA damage levels in the mitochondrial genome 
and different brain regions. By determining the mtDNA repair status in the central auditory system 
using a rat model of D-galactose-induced aging, Chen et al. observed a significant age-associated 
increase in mtDNA 4834 base pairs (bp) deletions and the number of terminal deoxynucleotidyl 
transferase–mediated uridine 5'-triphosphate-biotin nick end-labeling (TUNEL)-positive cells, a 
marker for apoptosis [30]. Interestingly, expression of Pol γ, the major mitochondrial Pol, and OGG1 
were remarkably down-regulated in the auditory cortex. Thus, potentially indicating that during aging, 
increased mtDNA damage likely resulted from a decrease in its DNA repair capacity. These findings 
are supported by the work of Gredilla et al. addressing the efficiency of BER throughout the murine 
lifespan in mitochondria from cortex and hippocampus, both of which are regions severely affected 
during aging and in neurodegenerative diseases [31]. OGG1 activity peaked at middle-age in cortical 
mitochondria, followed by a significant drop at old age. However, only minor changes were observed 
in hippocampal mitochondria during the whole lifespan of the animals. Furthermore, OGG1 activity 
was lower in hippocampal than in cortical mitochondria. Taken together, these data suggest an 
important region-specific regulation of mitochondrial BER during aging.  
The expression of OGG1 can also be modulated by many exogenous compounds, as shown by 
several studies discussed in the following. Cigarette smoke was found to induce DNA damage, as well 
as to alter OGG1 activity and distribution in several regions of the brain in neonatal mice; underlining 
the importance of cigarette smoke as risk factor for neurodevelopmental, as well as neurodegenerative 
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disorders [32]. Fenvalerate is a synthetic pyrethroid widely used as pesticide in agriculture in 
developing countries and acts as neurotoxic compound in adults. To investigate the potential toxicity 
of fenvalerate to developing organisms, Gu et al. treated zebrafish larvae with this pesticide and found 
that OGG1 expression was down-regulated in a concentration-dependent manner. Fenvalerate also 
caused brain impairment during zebrafish development, further underlining the toxic nature of the 
compound especially during development [33]. Another pesticide, the organochlorine dieldrin, is a 
known neurotoxicant ubiquitously distributed in the environment and is toxic for dopaminergic 
neurons in vitro. Dieldrin slightly up-regulated OGG1 activity in proliferating PC12 cells, while the  
8-oxo-G levels remained unchanged [34]. Differentiated PC12 cells on the other hand showed a longer 
lasting decline in OGG1 activity and a concomitant increase in 8-oxo-G levels. The differences 
between proliferating and differentiated cells might explain at least in part the vulnerability of post-mitotic 
neurons to oxidative stress and neurotoxins. A study that analyzed the impact of developmental 
exposure to lead (Pb), a known inducer of oxidative stress in the brain, found that cerebral 8-oxo-G 
levels were only transiently modulated early in life, at postnatal day 5, but were markedly elevated 20 
months after the exposure had ceased [35]. OGG1 activity itself was not altered by developmental Pb 
exposure, resulting in loss of the age-dependent inverse correlation between OGG1 activity and 8-oxo-G 
accumulation. Exposure to Pb in old age did not have an impact on 8-oxo-G levels, suggesting that 
age-related oxidative damage accumulation and neurodegeneration could be markedly influenced by 
developmental disturbances.  
Along the line of OGG1 involvement in development, OGG1 was found to be important for the 
determination of neural stem cell (NSC) differentiation by repairing mtDNA damage in differentiating 
neural cells [36]. NSCs derived from OGG1 knockout (ko) mice spontaneously accumulated mtDNA 
damage and shifted their differentiation direction toward an astrocytic lineage. A similar phenotype 
was observed when wild-type (wt) NSCs were subjected to mtDNA damaging insults, thus suggesting 
that mtDNA damage might be one of the primary signals for elevated astrogliosis and the lack of 
neurogenesis, a phenomenon observed after neuronal injury. Another study also demonstrated that 
small interfering RNA (siRNA) mediated knockdown (kd) of the DNA glycosylases OGG1 and 
endonuclease VIII (Nei)-like protein (NEIL) 3 decreased the differentiation ability of NSC, resulting in 
a decline of both neuronal and astrocytic gene expression after mitogen withdrawal, as well as a 
decrement in the stem cell marker Musashi-1 [37]. This suggests that OGG1 plays a role in governing 
essential NSC characteristics.  
Besides the above-described impacts on development and ageing, alterations in OGG1 have been 
associated with numerous neurodegenerative disorders as elaborated bellow. 
2.1.1.1. Parkinson’s Disease 
The primary cause of Parkinson’s disease (PD), the second most common age-related 
neurodegenerative disorder [38], is still unknown. However, the pathogenesis of PD has been linked to 
mitochondrial dysfunction and oxidative stress (reviewed in [39,40]). Both of these factors are 
regarded as important contributors to neuronal death in the substantia nigra (SN) of PD patient brains. 
Indeed, besides increased 8-oxo-G levels [41], it has been shown that, among several other DNA 
glycosylases, OGG1 is up-regulated in the SN of PD patients [42]. The potential involvement of 
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OGG1 in PD was further supported through the finding that aged OGG1 ko mice developed an age-
associated mild parkinsonian phenotype, which manifested among others in spontaneous locomotor 
behavior and decreased striatal dopamine levels [43]. Furthermore, this study showed that young 
OGG1 ko mice were more susceptible to the dopaminergic toxin 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine than their wt littermates. Finally, an age-associated increase in 8-oxo-G levels was 
seen in this mouse model, further validating this mouse strain as a possible model for PD. Nakabeppu 
et al. showed a significant increase in 8-oxo-G in mtDNA as well as an elevated expression of 8-oxo-G 
dGTPase (MTH1), OGG1 and MutY glycosylase homologue (MUTYH) in nigrostriatal dopaminergic 
neurons of PD patients, suggesting that the buildup of oxidized DNA lesions may be involved in the 
loss of dopaminergic neurons [44]. Furthermore, MTH1-null mice, exhibiting an increased accumulation 
of 8-oxo-G in striatal mtDNA, displayed a more extreme neuronal dysfunction after 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine administration than wt mice; potentially indicating that oxidative DNA 
damage presents a major risk factor for PD.  
The OGG1 S326C polymorphism is commonly associated with an increased risk for various kinds 
of cancer, such as lung [45] and breast cancers [46]. Coppedè et al. investigated whether the 
occurrence of PD correlates with the OGG1 S326C polymorphism by screening 139 sporadic PD 
patients and 211 healthy matched controls [47]. Neither did the allele frequency of C326 differ 
between the groups (0.20 in PD patients and 0.19 in controls; p = 0.817), nor did the differences in 
genotype frequencies. Furthermore, there was no association of S326C with the disease age at onset  
(p = 0.791). Overall, these results suggested that the OGG1 S326C polymorphism is not associated 
with sporadic PD.  
Taken together, OGG1 seems to have a crucial influence on the pathogenesis of PD, but more 
studies are needed to shed light on the exact mechanism connecting oxidative DNA damage and PD.  
2.1.1.2. Amyotrophic Lateral Sclerosis 
Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disease with adult onset 
(reviewed in [48]). It is characterized by progressive degeneration of motor neurons in the anterior 
horn cells of the spinal cord, the brain stem and the cerebral cortex. Increased levels of 8-oxo-G have 
been found in the spinal cords of ALS patients [49] and further evidence hints at a deficiency in 
mtDNA repair underlying the pathogenesis of ALS (reviewed in [39]). A study analyzing the 
association of the OGG1 S326C polymorphism in sporadic ALS found that both the C326 allele  
(p = 0.02) and the combined S326C + C326C genotype (OR = 1.65, 95% CI = 1.06–2.88) increased 
the risk of ALS [50]. Even though the risk was higher, no significant association between the disease 
phenotype and the S326C polymorphism, with respect to the age, onset site, as well as disease 
progression, could be observed. These results suggested a possible involvement of the human OGG1 
S326C polymorphism in the pathogenesis of sporadic ALS. 
The Cu/Zn-superoxide dismutase 1 (SOD1) is an antioxidant enzyme that converts superoxide 
anions (O2–) to hydrogen peroxide (H2O2) and thus contributes to the control of the oxidative DNA 
damage levels. Murakami et al. used transgenic mice carrying mutant SOD1 as an animal ALS model 
to analyze the expression of OGG1 [51]. They found that the nuclear form of OGG1 was up-regulated 
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in presymptomatic mice, while mitochondrial OGG1 levels remained stable, thus potentially indicating 
that the de-regulation of protective mechanisms against oxidative stress could contribute to ALS. 
2.1.1.3. Triplet Repeat Expansion Diseases 
There are at least 18 different neurological diseases, among them Huntington’s disease (HD) and 
several inherited ataxias, that have been linked to the expansion of trinucleotide repeats (TNRs) in the 
human genome (reviewed in [52]). In HD, CAG triplet expansion occurs in the Huntingtin gene in 
post-mitotic neurons and results in altered interaction of the Huntingtin protein with other binding 
partners (reviewed in [39]). OGG1 has been suggested to play a role in this pathogenesis through the 
initiation of the BER pathway to excise 8-oxo-G present in these tracts [53]. This study suggested a “toxic 
oxidation” model in non-dividing cells by which the OGG1-initiated repair of 8-oxo-G triggers an 
iterative oxidation-excision cycle that culminates in progressive age-dependent expansion of the CAG 
repeats. The model predicts that triplet repeat expansion results from error-prone repair steps 
downstream of OGG1 and APE1 action, namely by strand displacement/slippage of the Pol during 
gap-filling reaction. Such slippage results in the formation of a hairpin structure, which gets stabilized 
by MSH2/MSH3, and cannot be recognized by FEN1 for flap trimming, since the 5' end of the flap is 
hidden in the hairpin structure. Importantly, this somatic age-dependent expansion is independent of 
cell division, as it takes place in terminally differentiated cells. Maybe somewhat surprisingly the largest 
expansions in TNRs occur in non-dividing tissues, where besides the BER-mediated toxic oxidation also 
nucleotide excision repair (NER) pathway has been implicated in pathogenesis of TNR expansions 
(reviewed in [54]). Several models have also been proposed to account for the TNR expansion in 
dividing tissue [54]. Interestingly, Jarem et al. showed that, while OGG1 activity is comparable on 
duplexes (i.e., linear dsDNA molecules) containing either TNR or a mixed sequence, OGG1 shows a 
reduced affinity and excision activity for 8-oxo-G in hairpin substrates [55]. These findings suggest 
that 8-oxo-G accumulates at hairpin structures, which can subsequently be incorporated into duplexes, 
thus giving rise to a TNR expansion that still contain unrepaired 8-oxo-G lesions capable of starting 
yet another toxic cycle of expansion. In contrast to Kovtun et al. a study by Lin et al. showed that the 
kd of OGG1 and APE1 did not affect repeat instability [56]. This discrepancy to the above mentioned 
data might well be a result of cell-line specific effects. Interestingly, CAG repeat expansion in HD is 
targeted preferentially to the striatum, while other brain regions, such as the cerebellum, remain 
spared. Investigating this phenomenon, Goula et al. found that oxidative DNA damage abnormally 
accumulates at CAG repeats in a length-dependent, as well as age- and tissue-independent manner in 
HD mice [57]. Analysis of protein levels and enzymatic activities in the striatum and cerebellum of 
HD mice, showed a striatum-specific down-regulation of proteins acting in the BER pathway 
downstream of OGG1, correlating with increased somatic CAG instability in the striatum over the 
cerebellum in HD mice. This suggests that the relative levels of BER proteins in different tissues 
potentially contribute to the disease manifestation. Besides wt OGG1, a recent study investigated the 
influence of the OGG1 S326C polymorphism on HD [58]. Both mono- or biallelic bearers of the 
mutant S326C allele tended to have an increased number of CAG repeats within the expanded HD 
allele (p = 0.049). Furthermore, mainly heterozygous subjects showed a significant (p = 0.041) earlier 
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disease onset than OGG1 wt individuals, suggesting a possible role of the human OGG1 S326C 
polymorphism in the development of HD.  
2.1.1.4. Stroke/Ischemia/Hypoxia 
Stroke is the third leading cause of death worldwide and its prevalence is steadily increasing 
(reviewed in [59]). It is mainly caused by thrombosis, embolism or hypotension and leads to a 
reduction of the blood flow insufficient to sustain normal cellular function (ischemia). Since the brain 
is an organ that consumes a large amount of oxygen, it is considered to be exposed to increased levels 
of oxidative DNA damage. The capacity to repair the oxidized DNA lesions is regarded as an 
important factor that determines neuronal survival after an ischemic insult (reviewed in [60]). Several 
studies have investigated means by which levels of OGG1 are regulated in different neuronal tissues 
upon ischemia and reperfusion. The results are quite heterogeneous and seem to depend largely on the 
model system used and analyzed. A study done by He et al. investigated the role of oxidative DNA 
damage in secondary remote tissue damage within the ventroposterior nucleus (VPN) after distal 
middle cerebral artery (MCA) occlusion in hypertensive rats [61]. Immunohistochemical analysis of 
the ipsilateral VPN revealed an increase in 8-oxo-G, while OGG1 immunoreactivity significantly 
decreased two weeks after cortical infarction (all p < 0.01). These findings, together with the notion 
that ebselen, a glutathione peroxidase mimic, significantly attenuated the loss of neurons and 
counteracted the effects in 8-oxo-G and OGG1, suggest a potential involvement of oxidative DNA 
damage in ischemia-induced delayed neuronal death within the VPN region. To understand the impact 
of oxygen and glucose deprivation on BER in two different regions of the hippocampus (CA1 and 
CA3/fascia dentata), Rolseth et al. measured the enzyme activities and gene expression levels of DNA 
glycosylases and AP-endonucleases in organotypic rat hippocampal slice cultures [62]. They found 
that under basal conditions AP-endonuclease activity and base removal of 1,N6-ethenoadenine (εA) 
and 8-oxo-G were approximately 20%–35% higher in the CA3/fascia dentata than in the CA1 region. 
In contrast to the AP-endonuclease activity and εA base removal, 8-oxo-G excision did not 
significantly change after 30 min or 8 h of oxygen and glucose deprivation. Additionally, reverse 
transcription-quantitative polymerase chain reaction (RT-qPCR) showed no changes in the 
transcription of OGG1 or any other of the investigated DNA glycosylases in response to a treatment of 
30 min. The study however did not investigate transcriptional levels at later time points. The authors 
concluded that the relatively low capacity for BER under basal conditions and the apparent failure to 
up-regulate the repair of oxidative damage after oxygen and glucose deprivation might contribute to 
the high vulnerability of the hippocampal CA1 region to ischemic injuries.  
A brief period of sublethal preconditioning ischemia can attenuate the injury extent arising from 
subsequent severe ischemia, possibly involving the activation of a variety of pathways that promote 
neuronal survival. Li et al. investigated whether BER could be induced as endogenous adaptive 
response, preventing the detrimental effect of oxidation damage, in a rat model where several episodes 
of ischemic preconditioning were applied prior to MCA occlusion to mimic a stroke [63]. In this study, 
ischemic preconditioning markedly reduced the nuclear accumulation of 8-oxo-G and other oxidized 
DNA lesions, leading to a decreased DNA damage response measured by p53 activation and 
nicotinamide adenine dinucleotide (NAD) depletion. Furthermore, measurements of BER activities in 
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nuclear extracts revealed that Pol β-mediated BER was markedly increased after ischemic 
preconditioning, likely as a result of an increase in the expression of Pol β, APE1 and OGG1 [63]. 
These results suggest that the protective effects of ischemic preconditioning might be partly due to 
enhanced repair of endogenous oxidized DNA lesions. Subsequent analysis of OGG1 ko mice revealed 
that OGG1 protects neurons against ischemia-induced oxidative DNA damage, as measured by 
accumulation of 8-oxo-G in the brain, and changes in cell death levels [64]. In contrast to the findings 
of Rolseth et al., this study showed an ischemia-induced elevation of 8-oxo-G incision activity 
resulting from an increase in the levels of a nuclear OGG1 isoform, peaking at around 6 h post 
treatment, thereby suggesting an adaptive response to oxidative nuclear DNA damage. From this it 
seems that OGG1 plays a role in reducing brain damage and improving functional outcome after 
ischemia by repairing oxidatively damaged nuclear DNA. Ischemia/reperfusion has been shown to lead 
to elevated matrix metalloproteinase activity, which further promoted (i) the degradation of the two 
important DNA repair proteins poly-ADP ribose polymerase 1 (PARP1) and XRCC1 and (ii) the 
accumulation of oxidative DNA damage after an ischemic stroke [65]. Concomitantly, analysis of 
primary cortical neurons subjected to oxygen-glucose deprivation displayed a marked decrease in 
OGG1, among other BER proteins [66]. Thus, it seems that the intranuclear gelatinase activity of 
matrix metalloproteinases acts in an intrinsic apoptotic pathway that is activated as a response to DNA 
damage in neurons during acute stroke injury. 
Hypothesizing that ischemia-reperfusion injuries in the spinal cord caused 8-oxo-G production and 
thus activated the DNA repair system involving OGG1, Lin et al. analyzed the spinal cords of rabbits 
after infrarenal aortic occlusion from 1 h to 48 h of reperfusion [67]. The results demonstrated that  
8-oxo-G was present in the grey matter after reperfusion and that, among other DNA repair proteins, 
the levels of OGG1 were markedly increased, peaking at around 6 h after reperfusion. Therefore, it seems 
that DNA repair proteins are rapidly expressed after spinal cord ischemia and subsequent reperfusion.  
Hyperoxic reoxygenation of asphyxiated newborns could cause increased damage to DNA. To 
investigate this matter, and also to test whether therapeutic hypothermia might attenuate the 
development of brain damage after asphyxia, newborn pigs were subjected to hypoxia followed by 
either normothermia or total body cooling [68]. 8-oxo-G was found to be elevated in the urine of 
hypoxic pigs, but these levels were not affected by hyperoxia or hypothermia. 8-oxo-G levels in brain 
and liver tissue did not change after any treatment. OGG1 expression in the hippocampus and the liver 
was down-regulated by hypothermia, without influencing the accumulation of oxidative DNA damage 
in genomic DNA. Also expression of OGG1 in the brain was not affected by hyperoxia. Thus, this 
study confirmed an increase in oxidative stress after hypoxia. In addition, DNA repair glycosylases 
were shown to be down-regulated by hypothermia but this had no effect on the accumulation of 
oxidative damage in genomic DNA.  
2.1.1.5. Alzheimer’s Disease 
Alzheimer’s disease (AD) is a progressive neurodegenerative disease characterized by memory 
impairment, cognitive decline and behavioral changes. As such, it is the most common age-associated 
severe dementia. Molecular mechanisms that lead to AD are slowly being unveiled and include the 
deposition of amyloid β-peptide (Aβ) plaques as well as accumulation of oxidized base damage both in 
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the nuclear as well as the mtDNA (reviewed in [39]). Still, the involvement of DNA repair in the 
pathogenesis of AD is far from being completely understood.  
An increase in oxidative DNA damage and a concomitant reduction in OGG1 mediated BER were 
detected in vulnerable brain regions in various stages of AD (reviewed in [39]). A study investigating, 
whether oxidative DNA damage is already present in a recently described preclinical stage of AD 
showed a significant increase in 8-oxo-G levels as well as elevated OGG1 protein levels in the 
hippocampus and the parahippocampal gyri [69]. Furthermore, an increase in OGG1 mRNA was 
measured in the superior and middle temporal gyri. Summarizing, these data suggested that oxidative 
damage to DNA induced a compensatory increase in OGG1 expression early in the pathogenesis of AD. 
Feng et al. showed that Aβ induces oxidative DNA damage in murine brains, and that this effect 
can be counteracted by soybean isoflavones (SIFs), previously found to exhibit neuroprotective effects 
by suppression of oxidative stress [70]. Mechanistically, mRNA and protein levels of OGG1 were  
up-regulated by SIFs, suggesting that the protective effects of SIF might be at least partly associated 
with the regulation of oxidative DNA damage repair by OGG1. In a model system of AD using rabbits 
fed with a cholesterol-rich diet, it was shown that 8-oxo-G accumulated in the brain, primarily in the 
hippocampus, and induced a range of DNA repair activities [71]. In the same study, OGG1 was found 
to physically interact with the xeroderma pigmentosum group B-complementing protein (XPB), which 
may potentially account for a mechanism involving these DNA repair responses. Furthermore, in 
contrast to wt mice, mice lacking OGG1 showed no interleukin-6 (IL-6) activation but a drastic 
increase of the pro-inflammatory cytokine tumor necrosis factor-α (TNF-α), suggesting that  
OGG1 may be involved in cytokine production induced by high cholesterol levels, and thus  
affecting neurodegeneration.  
2.1.1.6. Involvement of OGG1 in other Neurodegenerative Disorders 
Depression is known to induce elevated oxidative stress levels in peripheral blood of affected 
patients [72]. However, a study by Teyssier et al. found no significant impact of depression on the 
expression of OGG1 and several other oxidative stress-response proteins in the prefrontal cortex [73]. 
They concluded that the pathogenic role of oxidative stress in the brain could thus not be inferred from 
the alteration of peripheral parameters. However, as many other studies have shown that the amount of 
8-oxo-G levels do not necessarily correlate with the levels of OGG1 (and other related proteins), it 
might have been interesting to measure the actual 8-oxo-G content in the brain in this study as well. 
Mitochondrial OGG1 was down-regulated both at mRNA and protein levels in a pilocarpine-induced 
status epilepticus in the hippocampi of male rats, suggesting that lowering of mitochondrial BER 
enzymes may aggravate mtDNA damage and mitochondrial deficiency after the onset of a status 
epilepticus [74]. 
Cockayne syndrome (CS) is a rare recessive childhood-onset neurodegenerative disease, 
characterized by a deficiency in the DNA repair pathway of transcription-coupled NER (TC-NER). 
Mice with a targeted deletion of the CSB gene are used as a model for this disease. It was found that a 
double kd of CSB and OGG1 did not enhance the neurodegenerative phenotype, suggesting that in this 
disease unrepaired endogenous lesions are mostly substrate for NER, but not BER [75].  
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In summary, OGG1 is an enzyme that has been widely implicated to play a role in various 
physiological states of the brain and neuronal tissue, and its function is correlated to the onset of many 
neurodegenerative diseases. Still, the exact mechanisms that lead to the respective disorders, as well as 
the reasons why the regulation of OGG1 in different brain regions is so divergent, are far from  
being understood. Further studies are needed to unequivocally clarify the precise role of OGG1  
in neurodegeneration.  
2.1.2. MUTYH 
MUTYH (also sometimes called MUTY or MYH) is, like OGG1, a DNA glycosylase of the  
helix-hairpin-helix (HhH) family. It mediates the removal of adenine (A) paired with an 8-oxo-G [76,77], a 
situation that arises when replicative Pols bypass 8-oxo-G in an inaccurate manner by inserting a 
wrong A instead of a correct C. With this action MUTYH gives rise to a novel BER pathway involving 
Pol λ that reconstitutes the correct C:8-oxo-G base pair, which is then a substrate for OGG1 ([78–80], 
and reviewed in [2]); Several nuclear as well as mitochondrial isoforms of MUTYH are present in 
mammalian cells [81]. Biallelic mutations in MUTYH predispose to a familial adenomatous polyposis 
variant called MUTYH-associated polyposis (MAP) [82]. However, no evidence of increased risk for 
cancers of the brain tissue has been found in MAP patients [83].  
Up to date, a limited number of insights have been obtained regarding the potential roles of 
MUTYH in the brain. A study using MUTYH ko mice showed that there was no time-dependent 
accumulation of 8-oxo-G in brain tissue [84]. Interestingly, Lee et al. showed that levels of one 
embryonic isoform of MUTYH could be detected in rat brains at the E14 embryonic stage, after which 
it decreased during embryonic and neonatal development, while new isoforms appeared and gradually 
increased in the neonate and adult brain [85]. It seemed that during embryonic development expression 
levels of MUTYH followed the expression profile of proliferating cell nuclear antigen (PCNA). In 
addition, these proteins also colocalized in the nucleus. At later time points, when the levels of PCNA 
declined, MUTYH was detected primarily outside the nucleus. An activity for excision of A opposite 
8-oxo-G was detected in all the extracts. Even though the authors suggested that MUTYH might be 
primarily involved in post-replicative repair of nDNA, it is possible that MUTYH might rather be 
involved in repair of mtDNA in post-mitotic neurons. 
Though not much is known about the detailed role of MUTYH in the brain DDR, alterations in the 
MUTYH homeostasis have been associated with various neurodegenerative diseases, such as PD. 
2.1.2.1. Parkinson’s Disease 
Analogous to OGG1 levels, Fukae et al. demonstrated in the same study that also the levels of 
MUTYH are up-regulated in the SN of PD patients, suggesting that MUTYH is involved in the 
maintenance of mtDNA in PD brain [42]. As mentioned earlier, Nakabeppu et al. were able to show a 
significant increase in 8-oxo-G in mtDNA as well as an elevation in expression of MTH1, OGG1, and 
MUTYH in nigrostriatal dopaminergic neurons of PD patients, suggesting that the accumulation of 
these lesions may be involved in the loss of dopaminergic neurons [44]. Following the same line,  
Arai et al. found by immunohistochemical and biochemical analysis that MUTYH was up-regulated in 
the mitochondria of the SN of PD patients [86]. Western blot analysis identified a 47 kDa molecule as 
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the major isoform in these brains. Surprisingly, this isoform was localized to the mitochondria and 
stemmed from the alpha4 mRNA, even though it lacks the mitochondrial targeting sequence.  
2.1.2.2. Stroke/Ischemia/Hypoxia 
Similarly to the OGG1 study [61], He et al. investigated the impact of oxidative DNA damage in 
the secondary remote tissue damage, within the VPN after distal MCA occlusion, in hypertensive rats 
with respect to the MUTYH expression [87]. Immunohistochemical imaging analysis showed a distinct 
nuclear and cytoplasmic distribution of MUTYH in the entire region of the VPN. Compared with the 
sham group, the number of MUTYH positive cells decreased upon surgery. Additionally, treatment 
with ebselen was able to significantly increase the levels of MUTYH compared to the controls. In 
summary, a marked decrease of MUTYH in the VPN after 2 weeks of MCA occlusion was observed, 
and this effect could be counteracted by ebselen.  
The same study that showed an increase of OGG1 levels after ischemia-reperfusion injuries in the 
spinal cord also demonstrated an increase of MUTYH levels after the treatment [67]. This suggested 
that indeed MUTYH levels could be up-regulated in response to spinal cord ischemia and subsequent 
reperfusion. Similarly, Lee et al. demonstrated a strong increase in MUTYH mRNA and protein levels 
upon respiratory hypoxia, accompanied by the formation of 8-oxo-G in vivo in rat brains [88]. In situ 
hybridization analysis revealed expression patterns of MUTYH mRNA in hippocampal, cortical and 
cerebellar regions. The same group demonstrated, that MUTYH is abundantly expressed in the rat 
brain, with isoforms that were exclusive to brain tissue and localized to neuronal mitochondria [89]. In 
addition, removal of 8-oxo-G induced by hypoxia was accompanied by a spatial increase in MUTYH 
immunoreactivity, as well as an increase in of one of the three mitochondrial MUTYH isoforms. Taken 
together, this suggested the existence of inducible and non-inducible MUTYH isoforms in the brain. 
Also, CoCl2, an agent that mimics hypoxia and induces oxidation damage, was found to induce 
damage to mtDNA, but not to nDNA, in rat neuronal PC12 cells [90]. This finding coincided with an 
elevation of MUTYH protein levels, further underlining the idea that mtDNA repair processes 
involving MUTYH can be induced by the presence of mtDNA damage. 
2.1.2.3. Involvement of MUTYH in Other Neurodegenerative Disorders 
Examining changes in the levels of selected DNA repair enzymes and mtDNA damage in retinas 
from the eyes of young and old rodents, Wang et al. found an age-dependent increase in 8-oxo-G that 
co-localized with the mitochondrial enzyme superoxide dismutase, suggesting damage to mtDNA 
primarily in photoreceptors and retinal ganglions [91]. The expression levels of MUTYH seemingly 
decreased with age, consistent with the idea that an age-related increase in mtDNA damage is likely 
due to a decreased repair capacity in aged retinas and thus may contribute to age-related retinal diseases.  
Equine Cerebellar Abiotrophy (CA) is a neurological disease found in Arabian horses caused by 
post-natal degeneration of the Purkinje cells of the cerebellum. A linkage analysis discovered that  
CA-affected horses display reduced expression of MUTYH due to a single nucleotide polymorphism 
(SNP) approximately 1200 bp upstream of the MUTYH gene, which is adjacent to a possible site for 
the transcription factor GATA2 [92]. The authors suggested that this SNP might have a regulatory 
effect on MUTYH by negatively affecting the affinity of GATA2 and thus contributing to the onset of CA. 
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Taken together, the evidences point at a potentially important role of MUTYH in the pathogenesis 
of neurodegenerative diseases such as PD and stroke, as well as age-dependent retinal degeneration 
and equine cerebellar abiotrophy. Given the importance of OGG1 in oxidation damage disorders, it is 
not surprising that MUTYH may also be implicated in some of these diseases, as it acts in a pathway 
that is very much depending on OGG1. It would be interesting to see whether also the entire pathway 
for correction of A: 8-oxo-G mismatches downstream of MUTYH, involving Pol λ and some of the 
LP-BER components, is of similar importance.  
2.1.3. MBD4 
The methyl-CpG binding domain protein MBD4 (also known as MED1) is a DNA glycosylase that 
belongs to the MBD protein family within the HhH domain superfamily. It processes a wide substrate 
range of DNA base lesions mispaired with guanine (G), such as uracil (U), 5-fluorouracil (5-FU),  
3,N4-ethenocytosine (εC) and T ([93–95], and reviewed in [7]), Mbd4 ko mice are viable and show no 
developmental defects [96,97]. Though lack of MBD4 does not lead to defects in mice, it has been 
found that MBD4 mRNA levels are significantly up-regulated in the hippocampus of both 
schizophrenia and bipolar disorders suggesting a potential involvement of this glycosylase in human 
neurodegenerative diseases [98]. To understand the exact mechanism how MBD4 contributes to these 
disorders, future studies are needed. 
2.1.4. NTHL1 
Endonuclease III-like 1 (NTHL1, also known as NTH1) is a DNA glycosylase that belongs to the 
family of endonuclease III-like 1 proteins, a subfamily of HhH DNA glycosylases. It catalyzes 
excision of ring fragmented purines or oxidized pyrimidines like thymine glycol (Tg), 4,6-diamino-5- 
formamidopyrimidine (FaPyA), FaPyG, 5-hydroxycytosine (5-OHC) and 5-hydroxyuracil (5-OHU) 
when paired to G in double stranded DNA ([99–106], and reviewed in [7]). It is assumed that loss of 
NTHL1 function can be compensated for by NEIL glycosylases, because NTHL1 ko mice show no 
abnormalities [107,108] As was the case for NEIL1 and NEIL2, also no association for NTHL1 with 
the risk of developing multiple sclerosis was found [109]. So far, nothing more regarding a possible 
role of NTHL1 in neurodegenerative diseases is known. 
2.2. The Endonuclease VIII-Like Glycosylases 
2.2.1. NEIL1 
NEIL1 is a DNA glycosylase that belongs to the family of endonuclease VIII (Nei)-like proteins. Its 
preferred substrates are damaged pyrimidines and purines, such as Tg, FaPyA, FaPyG and others, but 
also 8-oxo-G and 5-OHU in double stranded DNA and bubble structures ([102,103,105,108,110–119], and 
reviewed in [7,120]), NEIL1 ko mice display a phenotype very close to the metabolic syndrome, and 
harbor increased levels of DNA damage in their mtDNA [121]. NEIL1 mRNA has been detected in 
different mammalian tissues including the brain and both its mRNA and protein levels were shown to 
increase during S-phase [102]. Further, widespread NEIL1 expression was reported at all ages in mice and it 
even increased with age, as did FaPyG lesion (induced by treatment of DNA with N-[3H]methyl-N'-
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nitrosourea) excision activity in all brain regions tested [24]. By investigating the efficiency of 
mitochondrial BER during the murine lifespan in the cortex and hippocampus, Gredilla et al. found 
that, similarly to OGG1; NEIL1 activity reached its maximum at middle-age in cortical mitochondria 
followed by a significant drop at old age, while only minor changes were observed in hippocampal 
mitochondria [31]. In addition, NEIL1 DNA glycosylase activity was lower in hippocampal than in 
cortical mitochondria. These findings indicate that regulation of mitochondrial NEIL1 activity in the 
brain is region and age specific.  
Among other BER enzymes, Rolseth et al. investigated the impact of OGD on NEIL1 activity and 
gene expression levels in organotypic rat hippocampal slice cultures (particularly in the regions CA1 
and CA3/fascia dentata) [62]. While base removal of U did not differ between the two hippocampal 
regions, removal of 5-OHU was slightly less efficient in CA3/FD than in CA1. After 30 min of OGD 
an increase in the activity on εA by approximately 25% could be detected in CA1, whereas activities 
for 8-oxo-G, 5-OHU and U remained unchanged. Later, 8 h after OGD, none of the enzyme activities 
differed from control values. As for OGG1, transcription of NEIL1 was not changed in response to 
OGD treatment at time point 0 h.  
Englander et al. measured the expression and activities of BER enzymes during brain development 
where the physiological transition of neuronal cells from the proliferative to the post-mitotic 
differentiated state takes place [122]. Expression of NEIL1 increased during brain development 
concomitant with maintenance of the capacity for excision of 5-OHU from bubble structured DNA in 
the mature rat brain, suggesting a potential role of NEIL1 in the maintenance of the integrity of 
transcribed DNA in the post-mitotic brain. A recent study by Canugovi et al. demonstrates that NEIL1 
ko mice exhibit an impairment in memory retention, as assessed by a water maze test [123]. However, 
these mice did not display abnormalities in motor performance, anxiety or fear conditioning. 
Furthermore, the deficiency in NEIL1 results in an increase in brain damage after ischemia/reperfusion 
due to apoptosis. Also, in these mice the incision activity of 5-OHU in a bubble structure was lower in 
the ipsilateral sides of ischemic brains as well as in mitochondrial lysates of unstressed old ko mice, 
suggesting that NEIL1 is a central player in learning, memory and neuronal protection against ischemia. 
2.2.1.1. Involvement of NEIL1 in Neurodegenerative Disorders 
Several studies have addressed the importance of NEIL1 in neurological conditions, such as CS, 
multiple sclerosis and depression. Hypersensitivity of CSB-deficient cells to oxidative stress hint to a 
defect in oxidative DNA damage repair contributing to the phenotype. A study that examined the role 
of CSB in the repair of FaPyG and FaPyA, both substrates for NEIL1, found that CSB ko mice have a 
higher level of endogenous FaPyG and FaPyA in nDNA from brain, compared to wt mice [115]. 
Furthermore, CSB was co-immunoprecipitated and co-localized with NEIL1 in HeLa cells and 
stimulated NEIL1 activity in vitro. Depletion of CSB and NEIL1 from HeLa cells by short hairpin 
RNA (shRNA) strongly inhibited the repair of induced FaPyG, suggesting that CSB plays a role in 
repair of FaPyG lesions, possibly through the interaction with NEIL1. Further, these findings implicate 
that FaPyG and FaPyA lesions and thus NEIL1 may have a causal role in the pathogenesis of CS.  
No association of NEIL1 with the risk of developing multiple sclerosis could be found [109]. 
Similarly, the study by Teyssier et al., besides no significant changes in the OGG1 expression, did not 
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detect an impact on NEIL1 levels in the prefrontal cortices of the patients suffering from depression [73]. 
Using the HD transgenic R6/1 mouse model, very recently Mollersen et al. demonstrated that the 
deletion of exon 2 of NEIL1 in mice leads to a significant reduction in somatic TNR expansions, when 
compared to their NEIL1 wt littermates [124]. Interestingly, while it could also be detected in female 
mice, the reduction of somatic expansions was more pronounced in male mice. Additionally, the 
authors found that NEIL1 binds and excises 5-OHC much more efficiently in duplex DNA than in 
hairpin substrates, suggesting that NEIL1 initiated BER of cytosine-derived oxidized lesions could be 
involved in the initiation of TNR expansions, additionally to other DNA modifications. 
2.2.1.2. Stroke/Ischemia/Hypoxia 
As already mentioned, NEIL1 has been linked to changes in oxygen levels and pathological 
conditions such as ischemia and stroke [123]. By addressing the effect of hyperoxic reoxygenation and 
therapeutic hypothermia on the development of brain damage after asphyxia in newborn pigs, as 
described in the OGG1 subchapter, transcription of NEIL1 was significantly down-regulated in the 
hippocampus, cortex, striatum and liver upon hypothermia, [68]. However, no effect on the 
accumulation of oxidative DNA damage in genomic DNA could be visualized. Like OGG1, NEIL1 
expression in the brain was unaffected by hyperoxia. Thus, even though NEIL1 was down-regulated 
by hypothermia, this had no effect on the accumulation of oxidative damage in genomic DNA.  
In conclusion, NEIL1 seems to be important for the development of the brain, memory and 
learning, as well as in response to stroke and ischemia and it has been implicated in CS. What the exact 
roles of NEIL1 in the different parts of the brain are still remains unresolved and will be the subject of 
future studies. 
2.2.2. NEIL2 
Like NEIL1, NEIL2 belongs to the family of endonuclease VIII (Nei)-like proteins. Its preferred 
substrates are strongly overlapping with the ones of NEIL1 and include oxidized pyrimidines, such as 
Tg, 5-OHU, 5-OHC, 5,6 dihydrothymine and 5,6 dihydrouracil in double stranded DNA and bubble 
structures ([111,119,125], and reviewed in [7,120]). NEIL2 mRNA has been detected in the brain, but 
unlike NEIL1, the expression of NEIL2 was independent of the cell cycle stage [111]. Analysis of the 
distribution patterns in mouse brains showed widespread expression of NEIL2 at all ages, and the 
excision activity of chemically induced FaPyG lesions increased with age in all brain regions tested [24]. 
Rolseth et al. found that transcription of NEIL2 in two different regions of the hippocampus was 
not changed in response to OGD treatment at time point 0 h [62]. As was the case for NEIL1, 
expression of NEIL2 levels increased during the physiological transition of neuronal cells from the 
proliferative to the post-mitotic differentiated state in brain development [122]. This was concomitant 
with the maintenance of the capacity for excision of 5-OHU from bubble structured DNA in the 
mature rat brain, suggesting a role for NEIL1 and NEIL2 in the maintenance of the integrity of 
transcribed DNA in the post-mitotic brain. Similarly to NEIL1, no association between NEIL2 and the 
risk of developing multiple sclerosis was found [109]. Future studies are needed to completely 
understand if and how NEIL2 could be associated with different neurodegenerative diseases. 
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2.2.3. NEIL3 
Similarly to NEIL1 and NEIL2, NEIL3 also belongs to the family of endonuclease VIII (Nei)-like 
proteins. In contrast to the two former glycosylases, NEIL3 excises FaPyG and FaPyA lesions but is 
inactive on 8-oxo-G ([126,127] and reviewed in [7]). Additionally, the mouse ortholog was shown to 
remove a broad spectrum of DNA base lesions on single-stranded DNA substrates, including 
secondary oxidation products of 8-oxo-G, such as spiroiminodihydantoin and guanidinohydantoin, 
suggesting that NEIL3 prevents the accumulation of these cytotoxic and mutagenic lesions in 
mammalian cells [127]. Though NEIL3 ko mice are viable and fertile, NEIL3 has been implicated to 
play a role in hematopoiesis or the immune system, since it is preferentially expressed in 
hematopoietic tissues [128]. In brains of newborn mice, NEIL3 revealed a discrete expression pattern 
in the subventricular zone, the rostral migratory stream, and the hilar region of the hippocampal 
formation, all of which are brain regions known to harbor stem cell populations [24]. Expression of 
NEIL3 decreased with age, and in brains of old mice it could be only detected in layer V of the 
neocortex. The distribution of NEIL3 thus indicates a potentially specific role of this enzyme in stem 
cell differentiation. Along with this study, expression pattern analysis of NEIL3 in the brain during 
mouse embryonic development revealed a tight regulation at both temporal and spatial levels. High 
expression of NEIL3 was observed at embryonic days 12–13, which coincides with the start of 
neurogenesis [129]. Subsequently, the expression of NEIL3 decreased gradually, and it could not be 
detected anymore in adult brains by RT-qPCR. Interestingly, expression during embryogenesis and in 
newborn mice was observed in areas with neural stem and progenitor cells, such as the subventricular 
zone and the dentate gyrus, suggesting that brain areas with neurogenesis and a high proliferative 
potential specifically express NEIL3. Subsequently, Sejersted et al. demonstrated a profound 
neuropathology in NEIL3 ko mice, which was characterized by a reduced number of microglia and a 
loss of proliferating neuronal progenitors in the striatum after hypoxia-ischemia [130]. Furthermore, 
NEIL3 ko neural stem/progenitor cells displayed an inability to increase neurogenesis and a reduced 
capacity to repair oxidized base lesions in single stranded DNA, indicating that NEIL3 could occupy a 
highly specialized role to accurately repair DNA in rapidly proliferating cells. Another study also 
demonstrated that, similarly to OGG1, siRNA-mediated kd of NEIL3 decreased NSC differentiation 
ability, resulting in a decrease of both neuronal and astrocytic gene expression after mitogen 
withdrawal as well as a decrease in the stem cell marker Musashi-1 [37]. Furthermore, a deficiency in 
NEIL3 led to a decrease in cell proliferation along with an increase in heterochromatin protein 1γ 
immunoreactivity, a sign of premature senescence, while cell survival remained unaffected. This 
potentially suggests that OGG1 and NEIL3 play a role in governing essential neural stem  
cell characteristics.  
2.2.3.1. Stroke/Ischemia/Hypoxia 
Newborn pigs that were subject to hypoxia and in the following treated by either normothermia or 
total body cooling showed a significant decrease in transcription of NEIL3 in the hippocampus and 
cerebellum by hypothermia, but without effect on the accumulation of oxidative DNA damage in genomic 
DNA [68]. Like for OGG1 and NEIL1, NEIL3 expression in the brain was unaffected by hyperoxia.  
Int. J. Mol. Sci. 2012, 13 16191 
 
 
Taken together, NEIL3 seems to predominantly play a role in neuronal stem cells and in the 
proliferation stages of neurons, whereas it rather is down-regulated during later stages of life. Future 
studies designed to address the role of NEIL3 in neuronal tissue will shed more light on this issue. 
2.3. The Alkyladenine DNA Glycosylase 
The alkyladenine DNA glycosylase (AAG, also named MPG and APNG) is the repair protein that 
efficiently recognizes and removes different methylated DNA base lesions is [131]. AAG acts on 
several structurally diverse DNA damages such as 3-methyladenine, hypoxanthine (Hx), εA,  
7-methyguanine, 1-methylguanine, 1,N2-ethenoguanine and U [132–136]. Because of the lack of both 
an alpha-beta fold characteristic to uracil DNA glycosylases (UDGs), as well as a HhH, AAG forms a 
separate class of DNA glycosylases [7]. Human AAG is present in three different isoforms: A, B and 
C. The AAG protein levels vary throughout different human tissues, being especially high in the brain, 
lymph nodes, tonsils, testis and adrenal glands [137]. Strong AAG expression has been reported in the 
following brain regions: cerebral cortex, hippocampus, lateral ventricle and cerebellum [137].  
2.3.1. Involvement of AAG in Neurodegenerative Disorders 
AAG mouse models, such as AAG ko and AAG transgenic (AAG-Tg) mice, provided valuable tools to 
study the influence of AAG-initiated BER on brain development and neurodegeneration [138–141]. 
Treatment with the alkylating agents methylazoxymethanol (MAM) and methyl methanesulfonate 
(MMS) induced extreme cerebellar toxicity and dramatically impaired motor function in AAG-Tg 
mice, while these effects were suppressed in AAG ko animals [131,142]. These findings support the 
idea that AAG activity, induced by alkylation treatment, promotes accumulation of toxic BER 
intermediates, while loss of AAG prevents their formation, thus ensuring resistance. Though several 
lines of evidence strongly indicate that a lack of AAG-initiated BER prevents induction of alkylation 
induced cell death in different tissues [131,138,142,143], it is important to note that the impact of BER 
absence on cellular survival largely depends on the type of DNA lesions induced by alkylating 
treatment, as well as the affected cell type. One such example is the treatment of neuronal and 
astrocyte cell cultures, obtained from the cerebellum of wt or Aag ko mice, with either 
chloroacetaldehyde (CAA) or the alkylating agent 3-methyllexitropsin (Me-Lex). Treatment with both 
CAA and Me-Lex resulted in increased sensitivity of AAG ko neurons, while the sensitivity of AAG 
ko astrocytes did not differ from the wt cells [144]. Present studies clearly imply an essential and 
specific role of AAG-mediated BER in alkylation-mediated neurodegeneration.  
2.4. The Uracil DNA Glycosylases 
2.4.1. UNG 
The UDG family in eukaryotes can be divided into three subfamilies: the uracil N-glycosylase 
(UNG), the single-strand-specific monofunctional uracil DNA glycosylases (SMUGs) and the 
mismatch-specific uracil DNA glycosylases (MUGs). Although members of the UDG family have 
very diverse amino-acid sequences, they share a common alpha-beta fold present in the catalytic active 
site. Humans and mice have two different UNG isoforms, UNG1 and UNG2 localized in the 
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mitochondria and the nucleus, respectively [145]. UNG protein levels vary in different tissues and cell 
types. In the human brain UNG levels are (i) extremely high in cerebellar Purkinje cells and neuronal 
cells of the cerebral cortex; (ii) moderate expression is observed in neuronal cells of the lateral 
ventricle, and in cerebellar cells of the granular and molecular layer as well as in glial cells; while (iii) 
very low levels or no UNG is detected in glial cells of both the hippocampus and the lateral ventricle [137]. 
Several studies clearly demonstrated variations in the activity and levels of UNG with  
age [25,26,31,146,147]. Neuronal extracts prepared from the cerebral cortex of young (7 days), adult 
(180 days) and old (720 days) rats showed a dramatic decrease with age in the ability to remove U 
from the DNA [26]. Supplementation of these extracts with recombinant purified UNG, Pol β  
and T4 DNA ligase significantly restored the loss of BER in aging neurons [26]. Single cell gel 
electrophoresis experiments of neurons and astrocytes from the cortex of young, adult and old rats 
revealed a marked increase in the number of UNG sensitive sites with age; further indicating  
age-dependent decrease in UNG activity [25]. Additionally, analysis of nuclear and mitochondrial 
UNG activities in different brain regions (the caudate nucleus, frontal cortex, hippocampus, cerebellum 
and brain stem) of young and adult mice revealed an age-dependent decrease in mitochondrial  
UNG-initiated BER [146]. In contrast to mitochondria, no region- or age-specific differences were 
detectable in the UNG nuclear activity, with exception of the cerebellum where uracil incision capacity 
was reduced with age [146]. Gredilla et al. similarly reported reduced UNG1 action in cortical 
mitochondria, however they did not detect any age-dependent change in the U removal ability in 
hippocampal mitochondria, while in cerebellar mitochondria UNG1 activity reached its maximum at 
old age [31]. Taken together, present findings clearly indicate an important role of UNG in different 
brain regions and suggest that an age-dependent increase in damage to mtDNA might contribute to the 
normal aging process. 
2.4.1.1. Involvement of UNG in Neurodegenerative Disorders 
The impact of UNG-mediated repair on mtDNA stability and its role in neurodegeneration were 
clearly demonstrated through a recent study using a mutated UNG1 (mutUNG1) transgenic mouse 
model [148]. MutUNG1 removed in addition to U also T from mtDNA, thus promoting mitochondrial 
instability. Targeted hippocampal expression of mutUNG1 resulted in mtDNA toxicity, decreased 
mitochondrial respiratory activity, apoptosis, neurodegeneration and impaired behavior [148]. Absence 
of UNG also strongly influenced mitochondrial stability, with a significant increase in the frequency of 
the D-1 mtDNA deletion in UNG ko mice [149]. Exposure of UNG ko mice to a folate-deficient diet 
(FD), a condition frequently associated with stroke, dementia and certain psychiatric disorders, 
increased mitochondrial mutagenesis in the aged brain and induced a compensatory increase in 
mtDNA content [149]. Consequences of FD in UNG ko animals were cognitive defects and enhanced 
mood alterations, such as anxiety and desperation [150]. As a consequence of induced mitochondrial 
instability and accumulation of DNA damage in general, a lack of UNG in cultured hippocampal 
neurons directly promoted apoptosis coinciding with p53 up-regulation [151]. This is of particular 
importance during tissue repair after brain ischemia, where a major increase in infarct size was 
observed in UNG ko mice when compared to wt animals [152]. Besides its impact on neuronal 
survival and brain integrity in general, several findings clearly suggested an important role of UNG in 
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neurodegenerative disorders. Total protein analysis of temporal lobe autopsies from four tauopathies 
indicated a significant change in UNG protein levels [153]. Further, both the activity of  
UNG-mediated BER as well as UNG protein levels were decreased in the inferior parietal lobule (IPL) 
of 10 sporadic AD patients [154]. Changes in BER capacity were not only detectable in disease-affected 
regions such as the IPL, but were also present in unaffected regions like the cerebellum [154]. 
Interestingly, while total BER capacity decreased with age in the brain of healthy individuals as 
expected, most AD patients had low BER levels independently of their age [154]. Impaired  
UNG-mediated BER was also detected in brains of amnestic mild cognitive impaired patients and this 
defect correlated with the abundance of neurofibrillary tangles [154]. Current studies suggested that 
the balance of UNG-mediated BER is potentially important to prevent premature aging and the onset 
of neurodegenerative disorders.  
2.4.2. TDG 
The thymine DNA glycosylase (TDG) is a member of the MUG subfamily. Besides T, TDG 
recognizes and excises U, 5-FU, εC, 5-hydroxymethyluracil, 5-formylcytosine and 5-carboxylcytosine 
when base paired with G [155–163]. TDG ko in mice is embryonically lethal, suggesting an essential 
function of TDG during development [164,165]. While the expression of TDG in human brain is 
documented in detail, studies in rat brains indicated that similar to UNG, TDG levels were inversely 
correlated with age [166,167]. Future studies are needed to reveal a role of this unique glycosylase in 
brain integrity and consequentially in neurodegeneration. 
So far not much is known about the role of the remaining two members of the UDG family in brain 
development and homeostasis. 
3. BER Proteins other than DNA Glycosylases 
3.1. Apurinic/Apyrimidinic Endonuclease 1 
APE1 is a multifunctional enzyme with a pivotal role in BER, by processing AP sites, and in the 
regulation of transcriptional activity by redox activation of transcription factors (such as Fos and Jun) 
([168–176], and reviewed in [177]). Depletion of APE1 in cultured hippocampal and sensory neurons 
sensitized the cells markedly to oxidative DNA damage induced by H2O2, reflected in reduced cell 
viability, increased caspase-3 activity and histone H2AX phosphorylation (γH2AX) [178]. In contrast 
to depletion, APE1 overexpression was neuroprotective in dorsal root ganglion neurons exposed to 
cisplatin [179]. In addition, it has been shown that it is the DNA repair function of APE1 that is crucial 
for cell survival of post-mitotic cells exposed to oxidative stress [180]. Determining the APE1 activity 
in cortical astrocytic and neuronal extracts derived from young (7 days), adult (6 months) and old (2 years) 
rats revealed an age-dependent decrease in the activity in adult compared to the young animals [25]. 
This reduction remained with age and was therefore also apparent in old rats. Exposing young (3 months) 
and aged (30 months) rats to 100% oxygen, Edwards et al. showed in young animals a reflective 
increase of APE1 protein levels in the hippocampus and basal forebrain, whereas no significant 
changes were detected in aged rats, suggesting an impaired responsiveness to oxidative stress [181]. 
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3.1.1. Alzheimer’s Disease 
A study of the APE1 hippocampal expression in human AD brains revealed elevated APE1 levels 
both in senile plaques, a histopathological hallmark of AD, and in injured neurons [182]. This increase 
was further found to be localized to the nuclear fractions of AD brains [183], which was confirmed in a 
immunohistochemical analysis of the cerebral cortex, where an intensive nuclear APE1 signal in all 
cortical layers was detected [184]. Aβ, a major contributor to AD development, is known to induce 
oxidative stress in neurons [185]. Tan et al. investigated the impact of various Aβ concentrations on 
APE1 levels and cell survival in isolated rat hippocampal neurons [186]. Interestingly, treatment with 
high concentrations of Aβ (5 μM) caused a reduction in cellular APE1 levels and activity, which 
correlated with extensive neuronal degeneration of the cultured hippocampal neurons. In contrast, 
lower concentrations of Aβ (1 μM) induced APE1 expression and activity, resulting in no substantial 
loss of the neurons [186]. The cyclin-dependent kinase 5 (Cdk5) was shown to regulate APE1 through 
phosphorylation, leading to a reduction of its endonuclease activity [187]. Subsequent accumulation of 
DNA damage, together with the finding that levels of phosphorylated APE1 were increased in brain 
tissue from AD and PD patients, might implicate Cdk5-mediated APE1 phosphorylation in the 
development of these neurodegenerative disorders. Independently of the endonuclease activity, but 
through its redox function, APE1 was found to mediate neuroprotection against Aβ and H2O2 via 
induction of the glial cell-derived neurotropic factor (GDNF) receptor α1 transcription, thereby 
increasing the GDNF responsiveness [188]. In a very recent proteomic study, where neuronal cells 
were challenged with an Aβ peptide fragment (25–35), novel interaction partners of APE1 were 
identified [189]. Among them, (i) tropomodulin 3, involved in the synaptic activity; (ii) heterogeneous 
nuclear ribonucleoprotein-H1, a regulator of alternative splicing and (iii) the pyruvate kinase 3 isoform 
2, a key enzyme in the glycolysis; all of these factors might have a functional relevance for neuronal 
cell survival and Aβ resistance. In addition, a potential association between the APE1-D148E SNP and 
the onset of AD was investigated, however no significant correlation was found [190].  
3.1.2. Involvement of APE1 in other Neurodegenerative Disorders 
Decreased APE1 levels were found in patient cells affected by Ataxia with Oculomotor Apraxia 
Type 1 (AOA1) [191], a neurodegenerative disorder originating in mutations of the APTX  
gene [192,193], which results in a cellular aprataxin deficiency [194]. Comparable findings were also 
obtained in ALS patients, where frontal cortical APE1 levels, as well as activity were significantly 
reduced [195], and in some cases missense mutations within the APE gene were identified [196]. ALS 
manifests in the progressive loss of motor neurons [197] and appears in a sporadic as well as a familial 
form [198]. For the sporadic form, a significant association with the D148E APE1 polymorphism was 
shown [199]. In contrast to the analysis of frontal cortical levels, a study by Shaikh et al. indicated 
increased APE1 levels in the spinal cord and motor cortex of ALS patients and showed that protein 
extracts from this tissue samples were more proficient in in vitro processing of AP sites [200]. 
Hyperactivity of APE1 potentially also contributes to the genomic instability by resulting in an 
increased number of extremely harmful DNA breaks. 
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In a rat model where epileptic-like seizures were induced by the application of kainic acid (KA), a 
subsequent induction of APE1 expression was observed in KA-vulnerable brain regions (CA1, CA3 
and hilar subregions of hippocampus, pyriform cortex, amygdala and thalamus) [201]. Furthermore, 
APE1 colocalized with the BER protein XRCC1, the oxidative DNA damage marker 8-oxo-G, the 
tumor suppressor p53 and also with fragmented DNA, as assessed by TUNEL staining [201]. These 
findings thus indicate that BER is activated but not sufficient to counteract excitotoxicity-mediated 
neuronal cell death. 
3.1.3. Stroke/Ischemia/Hypoxia 
A cold injury-induced brain trauma (CIBT) mouse model revealed an early post-traumatic decrease 
of APE1 levels within the lesion, which preceded later DNA fragmentation [202]. Similar observations 
were made after severe traumatic cortical brain injury [203]. However, the outer boundary area that 
survived CIBT showed a significant increase in APE1 immunoreactivity [202]. Transient focal 
cerebral ischemia (FCI) [204] or a defined hypoxic-ischemic insult [205] resulted in decreased APE1 
protein levels, a reduction exclusively detected in the hippocampus. In addition, APE1 levels 
selectively decreased in the hippocampal CA1 neurons 2 days after transient global cerebral ischemia 
(GCI), which was followed by DNA fragmentation after 3 days [206]. Intra cerebral application of the 
pituitary adenylate cyclase-activating polypeptide (PACAP) in the context of transient GCI reversed 
the effect, by inducing APE1 expression in hippocampal CA1 neurons, which correlated with 
improved cell survival [207]. This neuroprotective effect of PACAP was dependent on the DNA repair 
activity of APE1, as was shown through a loss-of-function rescue attempt of APE1 deficient cells, by 
overexpressing DNA repair-incompetent APE1. Upon transient spinal cord ischemia, spinal APE1 
levels decreased while oxidative DNA damage increased [208]. Interestingly, an ischemic tolerance 
could be established by sub-lethal ischemic preconditioning, which resulted in subsequent  
up-regulation of APE1 levels and other BER proteins and therefore better neuroprotection in the case 
of severe ischemia [63]. On the other hand, APE1 overexpression was shown to increase cell viability 
of cultured hippocampal and sensory neurons after ionizing radiation-induced DNA damage [209]. 
Glutamate-induced oxidative DNA damage was found to cause an increase in APE1 expression in rat 
cerebral cortical neurons via a pathway involving the cAMP-response element-binding protein, thereby 
improving the DNA repair activity of oxidized lesions [210].  
In summary, the multifunctional enzyme APE1 is implicated in a broad spectrum of 
neuropathologies via both, its endonuclease and redox activity. However, the exact regulation of APE1 
in this context and the underlying mechanisms remain to be investigated. 
3.2. Polynucleotide Kinase 
The polynucleotide kinase (PNK) is a bifunctional enzyme exhibiting a 5'-DNA kinase and a  
3'-phosphatase activity [211]. The removal of 3'-phosphate groups renders DNA ends accessible for 
Pols, an important step for promoting BER upon base excision by either NEIL1, NEIL2 or NEIL3 
(reviewed in [212]). Highest expression in human tissues of PNK was observed in the spleen, testis, 
heart and pancreas, whereas brain levels were rather low [211,213]. PNK is known to interact during 
DNA repair with the scaffold protein XRCC1 [214]. Disruption of this interaction impairs the DNA 
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repair capacity following oxidative stress [215]. In order to rescue this phenotype, overexpression of 
3'-phosphatase-proficient PNK was needed, indicating the 3'-phosphatse activity to be critical for 
efficient repair of oxidative DNA damage. 
3.2.1. Involvement of PNK in Neurodegenerative Disorders 
A recent study by Shen et al. linked four mutations in the PNKP gene to an autosomal recessive disease 
characterized by microcephaly, early-onset, severe seizures and developmental delay (MCSZ) [216]. 
The mutations were either frame-shift mutations (T424Gfs48X and exon15Δfs4X) due to small 
deletions or duplications within the kinase domain, resulting in truncated PNK proteins or point 
mutations (L176F and E326K) within the phosphatase domain. Assessing the DNA repair capacity by 
comet assay in patient-derived lymphocytes after H2O2 or camptothecin treatment, revealed a 
significant impairment in the case of MCSZ cells compare to healthy controls and in addition, PNK 
protein levels were found reduced in these patient cells[216]. Interestingly, a further study showed  
in vitro that PNKT424Gfs48X, PNKexon15Δfs4X and PNKL176F mutant proteins exhibit a markedly decreased 
5'-DNA kinase activity [217]. However, a moderate reduction in the 3'-DNA phosphatase activity was 
only observed in the case of recombinant PNKL176F. Analysis of phosphatase and kinase activities in 
MCSZ patient cells with decreased mutant PNK levels [216], revealed an overall marked reduction [2,17]. 
Furthermore, alkaline comet assay analysis of cells from affected individuals exhibiting the 
PNKT424Gfs48X and PNKexon15Δfs4X mutations as well as of cells homozygous for PNKE326K, revealed 
inefficient repair of DNA strand breaks upon γ-irradiation, whereas camptothecin treatment only led to 
an accumulation of DNA damage in cells containing both, mutated PNKT424Gfs48X and PNKexon15Δfs4X [217]. 
Even though PNK appears to be crucial for proper neurodevelopment, further mechanistical studies 
will be needed to unravel the potential link between impaired DNA repair capacity and the 
development of MCSZ. 
3.3. DNA Polymerase β 
The DNA repair enzyme Pol β belongs to the X family of DNA Pols. In addition to the polymerase 
activity, exhibited particularly on short gaps, it also possesses a dRPlyase activity and associates with 
BER proteins such as XRCC1 and DNA ligase III [218–235]. Thereby, Pol β is considered to be the 
major BER Pol (reviewed in [236]). It is constitutively expressed in most tissues, with the highest 
levels found in testis and brain [237]. The generation of a Pol β ko mouse model revealed that, besides 
growth retardation and insufficient lung ventilation leading to immediate postnatal death, these mice 
also displayed altered neurogenesis [238]. The defect in neurogenesis was reflected in vast apoptotic 
cell death in the developing cortex, hindbrain and dorsal root ganglion. Additional ko of p53 in Pol β 
deficient mice (Pol β ko and p53 ko) abolished the neuronal cell death, thus proving the  
p53-dependency of this apoptotic pathway [239]. However, neonatal lethality remained even in the 
absence of p53. Ko of the DNA-dependent protein kinase catalytic subunit (DNA-PKcs), an enzyme 
involved in the non-homologous end-joining (NHEJ), in a Pol β deficient background exhibited even 
more pronounced growth retardation and neuronal apoptosis as well as earlier lethality compared to 
Pol β ko [240].  
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The fact that Pol β activity changes with aging was demonstrated in a study, where incubation of rat 
neuronal extracts from young, adult and old animals with synthetic 1 and 4 nucleotide gap constructs 
resulted in reduced BER capacity with age [241]. Though the gap repair activity was markedly 
impaired with age, complementation with rat liver Pol β rescued the activity. A further study by 
Cabelof et al. confirmed these findings by showing that Pol β activity, protein and mRNA levels 
decreased significantly in brain tissue with age by comparing young (4 months) and old (24 months) 
C57BL/6 mice [242]. The biological relevance of this age-associated decrease in Pol β was further 
underlined by the observed increased mutation frequency in old animals. Interestingly, caloric 
restriction was able to largely reverse this age-dependent decline [243]. 
3.3.1. Alzheimer’s and Parkinson Disease 
AD cell culture models demonstrated that the application of Aβ to cortical neurons induces cell 
cycle reentrance followed by DNA replication resulting in reflective apoptosis of these cells [244]. Pol β 
was shown to be a leading Pol mediating de novo DNA synthesis after Aβ-induced cell cycle 
reentrance and thereby to play a role in the neuronal loss [245]. Consequently, in Aβ-treated cortical 
neurons, Pol β was also found to co-immunoprecipitate with cell division cycle 45 (Cdc45) and the 
DNA primase in nucleoprotein fragments, implicating its association with the DNA replication fork [246]. 
Aβ treatment of neural progenitor cells induced Pol β expression, with the consequence of cell 
differentiation along the neuronal lineage [247]. However, Weissman et al. showed overall decreased 
Pol β protein levels in AD brain tissue accompanied by reduced single nucleotide gap-filling activity [154]. 
Cell cycle re-entry was also observed in cultured cerebellar granule cells treated with the neurotoxin  
1-methyl-4-phenylpyridinium (MPP+), which is known to mimic PD by selective toxicity against 
dopaminergic neurons [248]. MPP+-mediated cell death was accompanied by increased Pol β 
expression. Interestingly, reduction of Pol β activity by either inhibition with dideoxycitidine or the 
expression of a dominant negative Pol β variant in these cells attenuated the neuronal loss [248].  
3.3.2. Triplet Repeat Expansion Diseases 
Several studies addressed the role of Pol β in the CAG triplet repeat expansion associated with HD. 
Kovtun et al. showed in an in vitro OGG1-initiated BER assay, that Pol β tends to perform strand 
displacement DNA synthesis within CAG repeats instead of single-nucleotide incorporation, resulting 
in longer DNA products [53]. Thus indicating that the initiation of BER by OGG1 in a CAG sequence 
contributes to the TNR expansion by Pol β-mediated strand displacement. Supporting this finding, a 
further study showed that multinucleotide incorporation by Pol β results in strand displacement and the 
formation of CAG hairpins that become stabilized and promote repeat expansion [249]. Pol β was also 
shown to accumulate along CAG repeats in the striatum of HD mice, the brain region most susceptible 
to degeneration in HD patients (for more details see Chapter 3.6.) [57]. Furthermore, Goula et al. 
recently determined the protein levels of the major BER proteins in the striatum, as well as the  
HD-spared cerebellum of HD transgenic mice [250]. While it was previously shown that Pol β protein 
levels were not significantly changed in these tissues, DNA ligase I, FEN1, APE1 and XRCC1 levels 
were increased by at least 2-fold in cerebellum [57,250]. In addition, in vitro repair of AP-sites with 
either (i) purified BER proteins in the striatum-specific stoichiometry or (ii) with wt and HD mice 
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striatum extracts, was shown to be less proficient than cerebellar repair regardless of the sequence context 
[250]. The same study demonstrated that lesions within CAG repeats tend to be repaired via LP-BER 
and that this process is more efficient under cerebellar conditions compared to the striatal ones. 
Moreover, a lesion closer to the 3' end of the repeat sequence was more efficiently repaired than a 5' 
lesion, most probably due to the fact that the formation of stable hairpins becomes impaired the closer 
a lesion is to the 3' end of the repeat tract [250]. Taken together these findings suggest a potentially 
important role of Pol β mediated repair in the onset of triplet repeat expansion diseases, such as HD. 
3.3.3. Stroke/Ischemia/Hypoxia 
Pol β activity was observed to be up-regulated in cerebral cortical neurons of newborn piglets exposed 
to hypoxia, and this was suggested to be beneficial to reduce hypoxia-induced DNA damage [251]. 
Upon transient FCI in rats, an increase in markers for oxidative DNA damage, namely 8-oxo-G and 
AP sites could be detected [252]. These lesions were efficiently repaired during reperfusion in the 
surviving cortex, which was proposed to be at least partially due to a protective long-lasting  
up-regulation of Pol β expression as well as its activity. As already described for APE1, ischemic 
preconditioning also elevated the protein levels of Pol β as well as XRCC1 and DNA ligase III [253]. 
This up-regulation in particular of SP-BER proteins was implicated to play a pivotal role in the 
neuroprotection observed in subsequent severe ischemic episodes. 
Summarizing, Pol β was shown to be crucial for proper neurodevelopment, whereas later on Pol β 
levels decline in an age-dependent manner. In the context with AD, spurious de novo DNA synthesis 
contributes to neuronal loss. However, upon hypoxic insults, Pol β activity mediates neuroprotection. 
3.4. DNA Polymerases δ and ε 
The Pols δ and ε belong together with Pol α to the B-family of DNA Pols and are the main Pols 
involved in lagging and leading strand replication [254–257]. Due to this function as replicative Pols, 
their DNA synthesis accuracy is high on undamaged DNA templates (reviewed in [258]). Besides 
DNA replication, the role of Pol δ and ε in LP-BER is supposed to be the accurate elongation after 
repair synthesis initiated by Pol β [259].  
Even though Pol β was for a long time assumed to be the only Pol present in the brain, Pol δ and ε 
activities were reported in developing as well as aging rat cerebral cortical neurons [260]. Analyzing 
TNR expansions in Saccharomyces cerevisiae revealed an involvement of yeast Pol δ together with the 
DNA helicase Srs2 in blocking TNR expansion [261]. Also, Pol δ has been found together with the 
DNA helicase Werner syndrome protein (WRN) to be important in resolving TNR-based hairpin 
structures in HeLa nuclear fractions complemented with recombinant proteins [262]. 
3.5. X-Ray Repair Cross Complementing 1 Protein 
The XRCC1 protein represents a crucial scaffold protein in the BER [222,263]. Among other roles, 
its interaction with the Pol β and DNA ligase III contributes to the 1nt-gap filling reaction and 
subsequent DNA ligation especially in the context of SP-BER ([227,264–266], and reviewed in [267]).  
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In 1999, Fang-Kircher et al. analyzed for the first time mRNA levels of different DNA repair 
proteins in human brain tissue of deceased Down’s syndrome patients [268]. Interestingly, a significant 
up-regulation of XRCC1 mRNA was found in the temporal, parietal and occipital lobes of these 
patients. Increased XRCC1 expression might be explained by the higher levels of ROS detected in 
Down’s syndrome neurons [269]. However, frontal lobe and cerebellar levels of XRCC1 were equal or 
even significantly lower in comparison to those observed in control brains [268].  
That XRCC1 is particularly important in differentiated neurons for the repair of oxidative DNA 
damage has been shown in differentiated human SH-SY5Y neuroblastoma cells [270]. SH-SY5Y 
XRCC1 kd cells displayed lower survival upon treatment with the oxidizing agents menadione or 
paraquat compared to control cells. No differences between proficient and deficient backgrounds were 
detected in dividing (non-differentiated) SH-SY5Y cells. In contrast, treatment of dividing SH-SY5Y 
XRCC1 kd cells with Hx, an additional inducer of oxidative damage by generating extracellular H2O2, 
resulted in increased sensitivity [270]. Taken together, these results support the general idea that 
requirements for the DNA repair proteins largely depend on the type of oxidative damaged that is 
induced. Consistent with these findings, XRCC1 heterozygous primary mouse cerebellar granule cells 
as well as XRCC1 kd human fetal brain neurons displayed a higher sensitivity towards menadione 
treatment [270]. 
Isolated granule cells from a neuronal-specific XRCC1 ko mouse model (XRCC1Nes−Cre) exhibited 
impaired DNA repair capacity after exposure to H2O2, as assessed by comet assay [271]. Furthermore, 
neurons in different brain regions of XRCC1Nes−Cre mice accumulated DNA damage in an  
age-dependent manner, shown by increased amounts of persistent γH2AX foci, a known marker of 
DNA double-strand breaks (DSB) and most likely DNA single-strand breaks (SSB). Interestingly, 
histological analysis of the cerebellum revealed a marked p53-dependent loss of basket, stellate and 
Golgi interneurons, all of which are important for fine-tuning of the cerebellar output [271]. 
Furthermore, accumulation of γH2AX foci associated with gliosis and increased c-Fos staining within 
distinct hippocampal regions indicated altered hippocampal homeostasis [271]. These features closely 
resemble the neuropathological characteristics found in temporal lobe epilepsy [272]. In a rat model 
where epileptic-like seizures were induced by KA, an induction of XRCC1 was observed after 16 h of 
seizure-onset in KA-vulnerable brain regions (CA1, CA3 and hilar subregions of hippocampus, 
pyriform cortex, amygdala and thalamus) [201]. As KA is known to cause oxidative stress [273],  
up-regulation of XRCC1 was thought to happen as a compensatory mechanism for the increased levels 
of DNA damage. 
3.5.1. Alzheimer’s and Parkinson Disease 
The discovery of XRCC1 polymorphisms gave raise to studies investigating a potential 
predisposition to diseases [274]. AD belongs to the most common diagnosed age-related 
neurodegenerative disorders resulting in dementia and it is often histologically characterized by the 
presence of Aβ plaques, neurofibrillary tangles and severe neuronal loss (reviewed in [275]). Since the 
R194W XRCC1 polymorphism lies within a conserved amino acid residue sequence [274], its 
potential functional relevance for neurodegeneration was addressed in a case-control study focusing on 
the late-onset AD in a Turkish population [276]. An increased risk for late-onset AD in the presence of 
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the R194W polymorphism was proposed [276]. However, the risk estimates did not reach a 
statistically significant level and were not confirmed in a later comparable study among Han Chinese 
people [277]. It therefore remains under debate, whether the R194W XRCC1 polymorphism promotes 
the onset of AD. The analysis of two additional XRCC1 polymorphisms, namely R280H and R399Q 
revealed no dependency between allele frequency and the onset of AD [190]. However, an increased 
risk was found for the development of PD in the presence of XRCC1 R399Q [278].  
3.5.2. Stroke/Ischemia/Hypoxia 
XRCC1 is not only implicated in chronic neurodegeneration, but also in neuronal loss after acute 
central nervous system injuries, including the cerebral ischemia-reperfusion phenomenon [279]. It is 
well established, that brain ischemia/reperfusion, a condition that resembles a stroke, goes along with 
an excessive production of ROS (reviewed [280,281]). In mice subjected to transient FCI by occlusion 
of the MCA, it was shown that XRCC1 levels decreased shortly after reperfusion and remained low 
until 24 h in the total MCA territory [279]. The loss of XRCC1 coincided with a positive TUNEL 
staining, corresponding to fragmented DNA arising 24 h later. A CIBT mouse model further supported 
this observation, where a similar early decline in XRCC1 levels within the injured region preceded 
later DNA fragmentation [282]. Thus, these studies indicated a potential role of the early XRCC1 
decrease in the DNA damage-mediated neuronal cell death in traumatic brain regions [279,282].  
Taken together, the scaffold protein XRCC1 was shown to be particularly important for DNA repair 
in post-mitotic neurons. Further association with the Down’s syndrome, seizure episodes and ischemic 
insults render XRCC1 a critical player in CNS homeostasis. 
3.6. Flap Endonuclease 1 
The multifunctional enzyme FEN1 possesses a 5'→3'-exonuclease and a 5'-endonuclease  
activity [283–288]. The latter function is of special importance in the context of LP-BER, as FEN1 
removes the arising 5'-flap structures after strand displacement DNA synthesis, thereby allowing 
subsequent DNA ligation (reviewed in [289]). 
3.6.1. Triplet Repeat Expansion Diseases 
In the severe neurodegenerative disorder HD, BER initiated by OGG1 has already been implicated 
to contribute to the CAG trinucleotide expansion in somatic cells, as discussed above [53]. In addition, 
a study in HD mice showed, that oxidative damage specifically accumulates along CAG repeats in a 
length-dependent manner [57]. This event is specifically taking place in the striatum, the brain region 
most prone to degeneration in HD patients, when compared to the disease-spared cerebellum. Even 
though gap-filling activity is reduced in the striatum several factors, such as: (i) pronounced 
accumulation of Pol β at CAG repeats; (ii) promoted Pol β-mediated strand displacement activity; and 
(iii) low 5'-flap endonuclease activity by FEN1, contribute to the somatic instability in the context of 
LP-BER [57]. This is further in line with model of HD which suggests that the Pol β generated 
displaced strand, when not efficiently removed by FEN1, forms a hairpin structure that can become 
stably integrated leading to trinucleotide expansion. The stoichiometry between BER proteins seems to 
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be an important factor for tissue-specific trinucleotide expansion-vulnerability [57]. Elevated levels of 
FEN1 in the cerebellum were implicated to significantly contribute to the increased BER efficiency on 
CAG substrates observed by measuring the repair capacity with BER proteins in the cerebellar 
stoichiometry (discussed in more detail under 3.3.) [57,250]. This effect was not observed when BER 
efficiency was addressed under the striatum-specific conditions [250]. Liu et al. similarly reported that 
FEN1 might facilitate TNR expansion, however through a slightly different mechanism by alternate 
cleavage of hairpin structures arising during Pol β multinucleotide DNA synthesis and strand 
displacement during LP-BER [249]. As FEN1 is unable to process 3' ends of stable hairpins, it rather 
tends to cleave lose 5'-flaps of the hairpin, thereby providing ligatable nicks and potential TNR 
expansion. A comprehensive overview of the FEN1 involvement in the TNR expansion is presented in 
a recent review by Liu and Wilson [290]. 
3.7. DNA Ligase I/III 
The DNA ligase I in association with PCNA is targeted to the replication machinery where it is 
important for Okazaki fragment joining [291]. In the context of BER it acts in the final step of LP-BER 
by sealing nicked DNA (reviewed in [292]). The DNA ligase III, on the other hand, is mainly 
implicated in DNA ligation during SP-BER where it is in complex with the scaffold protein  
XRCC1 [265,266]. Both, the DNA ligase I and III are shown to be essential for proper embryonic 
development, as studied in mice (reviewed in [292]). Moderate expression of the DNA ligase I was 
found in the cerebellum, lateral ventricle and cerebral cortex, whereas levels in the hippocampus were 
rather low [137]. However, in comparison to cerebellar levels, DNA ligase I is markedly reduced in the 
striatum where it might be involved in the observed less efficient BER of lesions within CAG repeats, 
thus potentially contributing to TNR instability [250]. High levels of DNA ligase III were observed in 
the cerebellum and the cerebral cortex decreasing to moderate levels in the hippocampus and lateral 
ventricle [137]. A DNA ligase I deficiency described in a female patient was accompanied with 
continuous infections due to a compromised immune response, sensitivity towards sunlight, growth 
retardation and delayed development [292]. The neurodegenerative disorder spinocerebellar ataxia 
with axonal neuropathy-1 (SCAN1) originates from mutated tyrosyl phosphodiesterase 1 (TDP1), a 
protein involved in the repair of DNA SSB [293]. Interestingly, the DNA ligase III was found to 
directly interact with mutated TDP1 in SCAN1, forming a catalytically inactive complex, thereby 
potentially contributing to a defective SSB repair [294]. A further link between DNA ligases and 
neurodegeneration is given in the neurological disorder AOA1, where aprataxin, a protein important 
for the removal of adenylate groups at single-strand nicks [295], is mutated [192,193]. Therefore, 
deficiency in the processing of adenylate groups by aprataxin results in abortive ligation attempts by 
the DNA ligase III, which might result in the accumulation of DNA SSB [295].  
3.7.1. Stroke/Ischemia/Hypoxia 
As already observed for other BER proteins, ischemic preconditioning resulted in an induction of 
the DNA ligase III in neuronal and glial cells [253]. This up-regulation of the BER pathways was 
further reflected in the increased BER activity in nuclear brain extracts from preconditioned animals [253]. 
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In summary, even though not much is known so far about DNA ligases in the physiology and 
pathology of the CNS, initial hints point towards an involvement in distinct neurodegenerative disorders. 
4. Conclusions and Future Perspectives 
As a consequence of high oxygen metabolism, an efficient BER pathway is needed to ensure 
genomic stability and brain homeostasis. The majority of BER proteins are highly expressed in the 
brain, however present data clearly indicate that the expression pattern is not homogenous and that it 
differs from one brain region to another. In addition, levels of BER proteins change with age, resulting 
in accumulation of DNA lesions and genomic instability. Tissue-specific and age-dependent 
expression of major BER proteins suggests the existence of a very complex and highly regulated DDR 
in the CNS. This complexity is most probably also a reason why studies addressing the role of BER 
proteins in brain physiology and pathology, using various different models, resulted in different and 
sometimes contradictory observations. However, changes in BER protein levels and the DNA repair 
capacity have been correlated with some of the most common neurodegenerative disorders (Table 1), 
thus indicating the importance of understanding the mechanisms that ensure tight regulation of BER 
protein expression and activity. Though numerous studies compared the BER status between different 
brain regions during development, as well as between tissues of healthy individuals and patients 
suffering from various neurodegenerative disorders; still very little is known about the means by which 
BER is regulated in the brain. By revealing pathways important for balancing BER, we might be able 
to understand how changes in the BER capacity during lifetime, as well as neurodegeneration, 
contribute to aging and disease onset/progression, respectively.  
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